CTNNB1 and melanoma: Therapy response to anti-PD1 monotherapy showed an overall response rate (ORR) of 67% (6/9 patients) in patients with CTNNB1-mutant melanoma compared to 36% (49/135 patients) in those with CTNNB1-wild type tumors.